1. Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: Are effects maintained after stopping the programme?
- Author
-
Felipe Atienza, José A. De Velasco, Mónica Delgado, Manuel Anguita, Federico Vallés, Amador López Granados, Carmen Rus, Soledad Ojeda, and Federico Ridocci
- Subjects
Male ,medicine.medical_specialty ,Adrenergic beta-Antagonists ,Spironolactone ,Patient Readmission ,law.invention ,chemistry.chemical_compound ,Patient Education as Topic ,Randomized controlled trial ,Quality of life ,law ,Intervention (counseling) ,medicine ,Humans ,Practice Patterns, Physicians' ,Disease management (health) ,Survival analysis ,Aged ,Mineralocorticoid Receptor Antagonists ,Heart Failure ,business.industry ,Disease Management ,Middle Aged ,medicine.disease ,Survival Analysis ,Outcome and Process Assessment, Health Care ,chemistry ,Spain ,Heart failure ,Multivariate Analysis ,Emergency medicine ,Quality of Life ,Physical therapy ,Female ,Cardiology Service, Hospital ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,Patient education - Abstract
The objective of the study was to evaluate whether improvements obtained during an intervention programme were maintained after the programme was stopped. 153 patients discharged with a diagnosis of heart failure (HF) were randomized to either usual care or an intervention programme, which included patient education, consultation with the cardiologist and monitoring in the Heart Failure Unit. After an average period of 16±8 months, the intervention programme was stopped. One year later, all the patients were re-examined to assess HF readmissions, all-cause mortality, quality of life, and prescribed medical treatment. During the 16±8-month treatment period, patients in the intervention group had a lower rate of HF readmissions (17% vs. 51%, p
- Published
- 2005
- Full Text
- View/download PDF